A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy Participants

Phase 1 Active not recruiting 24 enrolled Agios Pharmaceuticals, Inc.

RandomizedSequentialDouble-blindTreatment

Summary

The primary purpose of this study is to assess the safety and tolerability of a single dose of AG-236 administered subcutaneously in healthy participants.

Timeline

Start: 2025-07-07
Primary completion: 2026-02-11
Completion: 2026-08-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AG-236	Unknown	—	Subcutaneous

Indications

No indication recorded.